Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Abbott Laboratories (ABT – Research Report), PolyPid (PYPD – Research Report) and GoodRx Holdings (GDRX – Research Report).
Abbott Laboratories (ABT)
In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories, with a price target of $133.00. The company’s shares closed last Friday at $104.09.
According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of
Abbott Laboratories has an analyst consensus of Strong Buy, with a price target consensus of $128.60, a 23.2% upside from current levels. In a report issued on May 6, RBC Capital also maintained a Buy rating on the stock with a $125.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
PolyPid (PYPD)
In a report released today, Balaji Prasad from Barclays maintained a Hold rating on PolyPid, with a price target of $10.00. The company’s shares closed last Friday at $4.32, close to its 52-week low of $3.57.
According to TipRanks.com, Prasad is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for PolyPid with a $12.33 average price target.
GoodRx Holdings (GDRX)
Barclays analyst Stephanie Davis maintained a Buy rating on GoodRx Holdings today and set a price target of $10.00. The company’s shares closed last Friday at $7.48.
According to TipRanks.com, Davis has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on GoodRx Holdings is a Moderate Buy with an average price target of $9.50, which is a 17.9% upside from current levels. In a report issued on May 16, Raymond James also upgraded the stock to Buy with a $10.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ABT:
- Abbott call volume above normal and directionally bullish
- FDA posts Class I recall of Abbott HeartMate 3 LVAS implant kit
- Evercore ISI removes several healthcare names from ‘Tactical Outperform’ list
- Abbott Labs EVP of Finance Robert Funck Retires After 36 Years
- Abbott’s dissolving stent receives FDA approval for arteries below the knee
